Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
The NHS Commissioning Board (Operating under the name of NHS England)
NHS England, Rutland House Second Floor, Runcorn
Runcorn
WA7 2ES
UK
E-mail: Katie.noonan@nhs.net
NUTS: UK
Internet address(es)
Main address: https://nhsengland.bravosolution.co.uk
Address of the buyer profile: https://nhsengland.bravosolution.co.uk
I.2) Joint procurement
The contract is awarded by a central purchasing body
I.4) Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
NHS England — Midlands and East Branded Medicines — Tranche B
II.1.2) Main CPV code
33600000
II.1.3) Type of contract
Supplies
II.1.4) Short description
NHS Framework for the Midlands and East, Branded Medicines — Tranche B.
Offer reference number: CM/PHR/16/5524.
Period of framework agreement:
CM/PHR/16/5524 /01 — NHS Framework for the Midlands and East, Branded Medicines — Tranche B — 1.3.2019 to 28.2.2021 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
CM/PHR/16/5524 /02 — NHS Framework for the Midlands and East, Branded Medicines — Tranche B (Cytokine modulators and other monoclonal antibodies) — 1.3.2019 to 29.2.2020 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.
The Framework is intended for use by the Department of Health and Social Care, Public Health England and the NHS in England. The Framework may also be used by private sector contractors and agents working on behalf of the above.
II.1.6) Information about lots
This contract is divided into lots:
No
II.1.7) Total value of the procurement
Value excluding VAT:
590 071 764.00
GBP
II.2) Description
II.2.3) Place of performance
NUTS code:
UKF
UKG
UKH
Main site or place of performance:
Please refer to Schedule 8 of the Framework Agreement.
II.2.4) Description of the procurement
Products associated with the lots are listed on Document No. 05 of the Invitation to Offer.
Each individual National Product Code (NPC) pack description in each of the regions (Midlands and East of England) is deemed to be a separate product for the application of the award criteria.
There is no restriction on the number of products that bidders can offer for, or be awarded.
The framework agreement is intended for use by the Department of Health, Public Health England and the
NHS in England.
The framework may also be used by private sector contractors and agents working on behalf of the above.
II.2.5) Award criteria
Quality criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: See Above
Cost criterion: Price is not the only award criterion and all criteria are stated only in the procurement documents
/ Weighting: See Above
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2017/S 172-351970
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
07/02/2019
V.2.2) Information about tenders
Number of tenders received: 32
Number of tenders received by electronic means: 32
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
NHS Comissioning Boards (Operating under the name of NHS England)
Runcorn
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 590 071 764.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
Awarded suppliers:
— Amgen Ltd,
— Astellas Pharma Ltd,
— Aventis Pharma Ltd T/A Sanofi,
— Bayer Plc,
— Biogen Idec Ltd (Biosimilars),
— Bristol-Myers Squibb Pharmaceuticals Ltd,
— Chiesi Limited,
— Daiichi Sankyo UK Ltd,
— Eli Lilly & Company Limited,
— Ferring Pharmaceuticals Ltd,
— Gedeon Richter UK Ltd,
— Genzyme Therapeutics Ltd,
— Gilead Sciences Ltd,
— Ipsen Limited,
— Janssen-Cilag Limited,
— Leo Pharmaceuticals,
— Merck Serono,
— Merck Sharp & Dohme Limited,
— Mylan,
— Napp Pharmaceuticals Ltd,
— Novartis Pharmaceuticals UK Ltd,
— Novo Nordisk Ltd,
— Pfizer Limited,
— Pharmasure Ltd,
— Roche Products Limited,
— Rovi Biotech Limited,
— Sandoz Ltd,
— Takeda UK Ltd,
— Techdow Pharma England Limited,
— Teva UK Limited,
— UCB Pharma Ltd.
VI.4) Procedures for review
VI.4.1) Review body
The NHS Commissioning Board (Operating under the name of NHS England)
NHS England, Rutland House, Second Floor
Runcorn
UK
VI.5) Date of dispatch of this notice
13/02/2019